These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26669277)

  • 1. Role of levosimendan in the management of subarachnoid hemorrhage.
    Varvarousi G; Xanthos T; Sarafidou P; Katsioula E; Georgiadou M; Eforakopoulou M; Pavlou H
    Am J Emerg Med; 2016 Feb; 34(2):298-306. PubMed ID: 26669277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan in cardiac failure after subarachnoid hemorrhage.
    Busani S; Rinaldi L; Severino C; Cobelli M; Pasetto A; Girardis M
    J Trauma; 2010 May; 68(5):E108-10. PubMed ID: 20453750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Levosimendan in cardiopulmonary resuscitation.
    Varvarousi G; Stefaniotou A; Varvaroussis D; Aroni F; Xanthos T
    Eur J Pharmacol; 2014 Oct; 740():596-602. PubMed ID: 24972240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of levosimendan treatment of myocardial stunning and low-output syndrome after cardiac surgery].
    García-González MJ; Domínguez-Rodríguez A
    Rev Esp Cardiol; 2006 Aug; 59(8):851-2. PubMed ID: 16938238
    [No Abstract]   [Full Text] [Related]  

  • 7. The calcium sensitizer levosimendan improves carbon monoxide poisoning related stunned myocardium: a cardiac magnetic resonance study.
    Rocco M; Carbone I; Morelli A; Palantonio P; Rossi S; Spadetta G; Passariello R; Pietropaoli P
    Acta Anaesthesiol Scand; 2006 Aug; 50(7):897-8. PubMed ID: 16879479
    [No Abstract]   [Full Text] [Related]  

  • 8. Levosimendan, a new therapeutic approach to prevent delayed cerebral vasospasm after subarachnoid hemorrhage?
    Konczalla J; Wanderer S; Mrosek J; Gueresir E; Schuss P; Platz J; Seifert V; Vatter H
    Acta Neurochir (Wien); 2016 Nov; 158(11):2075-2083. PubMed ID: 27614436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: a promising treatment for myocardial stunning?
    Ellger BM; Zahn PK; Van Aken HK; Schmidt C; Brussel T
    Anaesthesia; 2006 Jan; 61(1):61-3. PubMed ID: 16409345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan: The current situation and new prospects.
    Moreno N; Tavares-Silva M; Lourenço AP; Oliveira-Pinto J; Henriques-Coelho T; Leite-Moreira AF
    Rev Port Cardiol; 2014 Dec; 33(12):795-800. PubMed ID: 25459636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of levosimendan in a patient during cardiopulmonary bypass.
    Iriz E; Erer D; Unal Y; Zor H; Ozkose Z; Ozdogan ME
    J Card Surg; 2007; 22(2):153-6. PubMed ID: 17338755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Milrinone and levosimendan during porcine myocardial ischemia -- no effects on calcium overload and metabolism.
    Axelsson B; Johansson G; Abrahamsson P; Gupta A; Tydén H; Wouters P; Haney M
    Acta Anaesthesiol Scand; 2013 Jul; 57(6):719-28. PubMed ID: 23517167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
    Sonntag S; Sundberg S; Lehtonen LA; Kleber FX
    J Am Coll Cardiol; 2004 Jun; 43(12):2177-82. PubMed ID: 15193677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
    Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
    Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sepsis-associated takotsubo cardiomyopathy can be reversed with levosimendan.
    Karvouniaris M; Papanikolaou J; Makris D; Zakynthinos E
    Am J Emerg Med; 2012 Jun; 30(5):832.e5-7. PubMed ID: 21530136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.
    Greif M; Zwermann L; Reithmann C; Weis M
    Acute Card Care; 2008; 10(3):185-90. PubMed ID: 18972629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.